We present a 61-year-old man with severe myasthenia gravis, nonresponsive to conventional therapy. The patient was treated with individualized homeopathy, demonstrating significant improvement on his clinical status and no disease symptoms.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752385 | PMC |
| http://dx.doi.org/10.1002/ccr3.3190 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Incidence, characteristics, and comorbidities of a complete unselected Danish cohort of patients with thymic epithelial tumors.
Acta Oncol
January 2025
Department of Oncology, Copenhagen University Hospital, Copenhagen, Denmark.
Background And Purpose: We report the incidence, characteristics, and comorbidities of the complete unselected Danish cohort of patients with thymic epitheliums (TETs), which may serve as evidence for guiding treatment, surveillance, and counselling of TET patients.
Patients And Methods: All patients diagnosed with TETs from January 1st, 2015, to December 31st, 2020, were identified using the Danish Pathology Data Registry. Data on patient characteristics, comorbidities, and tumor histology were collected from electronic medical records available for all patients.
[Neurology: what's new in 2024].
Rev Med Suisse
January 2025
Service de neurologie, Département des neurosciences cliniques, Centre hospitalier universitaire vaudois et Université de Lausanne, 1011 Lausanne.
In 2024, therapeutic and diagnostic advancements are shaping the field of neurology. Three new drugs show promise for treating myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. A new classification for Parkinson's disease has been proposed, while a neuroprosthesis is improving gait in advanced stages.
View Article and Find Full Text PDFMyasthenia Gravis as a Paraneoplastic Manifestation of Renal Cell Carcinoma: More Than a Coincidence?
Ann Neurosci
January 2025
Department of Neurology, Pushpagiri Institute of Medical Sciences and Research Centre, Thiruvalla, Kerala, India.
Background: Myasthenia gravis is an autoimmune neuromuscular disease primarily caused by autoantibodies against nicotinic acetylcholine receptors (AChRs) at the neuromuscular junction. However, extrathymic malignancies need to be considered in the elderly population.
Purpose: Although thymic malignancy is the most common tumour association, several extrathymic malignancies complicated with myasthenia gravis have been reported.
Ocular Myasthenia gravis: what predicts secondary generalization?
Acta Neurol Belg
January 2025
Pediatric Neurology Division, Department of Pediatrics, All India Institute of Medical Sciences, Rishikesh, 249203, Uttarakhand, India.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!